14.27
-0.79 (-5.25%)
| Previous Close | 15.06 |
| Open | 15.30 |
| Volume | 141,748 |
| Avg. Volume (3M) | 75,326 |
| Market Cap | 185,994,912 |
| Price / Sales | 2.11 |
| Price / Book | 1.28 |
| 52 Weeks Range | |
| Earnings Date | 5 Mar 2025 |
| Profit Margin | -115.91% |
| Operating Margin (TTM) | -61.41% |
| Diluted EPS (TTM) | -3.81 |
| Quarterly Revenue Growth (YOY) | 169.90% |
| Total Debt/Equity (MRQ) | 3.20% |
| Current Ratio (MRQ) | 2.07 |
| Operating Cash Flow (TTM) | -28.87 M |
| Levered Free Cash Flow (TTM) | -9.90 M |
| Return on Assets (TTM) | -14.52% |
| Return on Equity (TTM) | -28.48% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Prenetics Global Limited | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by ‘enhancing life through science’. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 19.88% |
| % Held by Institutions | 12.57% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Prudential Plc | 30 Jun 2025 | 427,963 |
| Stevens Capital Partners | 30 Jun 2025 | 17,382 |
| 52 Weeks Range | ||
| Median | 32.00 (124.25%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 29 Oct 2025 | 32.00 (124.25%) | Buy | 13.82 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |